A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Hepatitis B virus infection is a worldwide disease and is still the most common cause of
hepatocellular carcinoma (HCC).Existing treatments for hepatitis B infection have various
side-effects including renal toxicity and drug resistance or failure.